DTCFF.US Defence Therapeutics Inc
- Market cap
- USD 15.5M
- P/E
- -
- P/B
- 6.28x
- ROE
- -154.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is DTCFF.US undervalued?
Graham numberThe Graham number of Defence Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Defence Therapeutics Inc fundamental analysis
No fundamental analysis for Defence Therapeutics Inc yet.
Defence Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Defence Therapeutics Inc
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid …
Full company profileDefence Therapeutics Inc financial statements
Defence Therapeutics Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 |
| Operating Income | - | -673K | -2.86M | -7.30M | -6.55M | -12.8M | - | -4.99M |
| EBITDA | - | - | - | -7.34M | -6.59M | -12.7M | - | -4.95M |
| Net Income | - | -673K | -2.86M | -7.34M | -6.76M | -13.2M | - | -5.43M |
| EPS | - | -0.02 | -0.11 | -0.20 | -0.15 | -0.29 | - | -0.07 |
| Balance Sheet | ||||||||
| Total Assets | - | 1.91M | 5.61M | 720K | 3.53M | 478K | - | 6.51M |
| Total Liabilities | - | 48.4K | 122K | 1.11M | 1.97M | 4.06M | - | 3.00M |
| Shareholders' Equity | - | 1.86M | 5.49M | -388K | 1.57M | -3.58M | - | 3.51M |
| Cash & Short-term Investments | - | 1.87M | 5.45M | 507K | 2.79M | 56.5K | - | 1.88M |
| Cash Flow | ||||||||
| Operating Cash Flow | -3.15K | -133K | -2.29M | -6.04M | -6.52M | -4.29M | - | -4.34M |
| Capital Expenditure | 0.00 | 46.0K | 0.00 | 0.00 | 65.8K | 203K | - | 420K |
| Free Cash Flow | - | -179K | -2.29M | -6.04M | -6.58M | -4.49M | - | -4.76M |
| Ratios | ||||||||
| ROE | - | -36.1% | -52.1% | - | -431.8% | - | - | -154.8% |
| ROA | - | -35.2% | -51.0% | -1,020.5% | -191.4% | -2,761.5% | - | -83.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Defence Therapeutics Inc dividends
Defence Therapeutics Inc has not paid dividends in the last 7 fiscal years.
Who owns Defence Therapeutics Inc
- Insiders 9.98%
- Institutions 0.00%
- Public & others 90.02%
- Shares outstanding 76.1M
- Free float 68.3M
Defence Therapeutics Inc company profile
- Company name
- Defence Therapeutics Inc
- Ticker
- DTCFF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 7171 Rue Frederick-Banting, Montreal, QC, Canada, H4S1Z9
- Phone
- 514 947 2272
- Website
- defencetherapeutics.com
About Defence Therapeutics Inc
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; Radiopharmaceuticals program; the ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program. The company also offers Dendritic Cell (DC) cancer vaccines using Accum; a protein-based vaccine formulation against COVID and infectious diseases; and a cervical cancer vaccine. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Montreal, Canada.
Defence Therapeutics Inc management
4- Mr. Sebastien PlouffeFounder & Executive Chairman · born 1972
- Dr. Ryan Simms Ph.D.COO & Head of Radiopharmaceutical Programs
- Dr. Maxime ParisottoChief Scientific Officer
- Dr. Mark Lambermon Ph.D.Head of Quality & Operations